Marathon Oil Often Leads In Cost Progress (NYSE:MRO)

bjdlzx Marathon Oil (NYSE:MRO) is a company that has a known reputation as an operator. In the first quarter report, they burnished that reputation some more with the following announcement: Brought online 12 three-mile wells during first quarter, delivered at a total per foot well cost more than 20% below comparable two-mile lateral wells; first…

Read More

Inflation Progress May Be Bumpy, But Is Likely To Continue

Richard Drury Inflation Remains High, but Is Improving in More Economies Historical analysis does not guarantee future results. OECD: Organisation for Economic Co-operation and Development Major economies’ core inflation based on local Consumer Price Index As of March 27, 2024 (Source: Haver Analytics, OECD and AllianceBernstein (AB)) Inflation, one of many inputs to multi-asset decision-making,…

Read More

Progress Software Corporation (PRGS) Q1 2024 Earnings Call Transcript

Progress Software Corporation (NASDAQ:PRGS) Q1 2024 Earnings Conference Call March 26, 2024 5:00 PM ET Company Participants Michael Micciche – VP, IRYogesh Gupta – CEOAnthony Folger – CFO Conference Call Participants Ray McDonough – Guggenheim SecuritiesFatima Boolani – CitigroupAntonio Venturim – JefferiesPinjalim Bora – JPMorgan Operator Good day and welcome to the Progress Software Corporation…

Read More

VOXX International: Despite Important Progress But Near-Term Prospects Remains Weak (VOXX)

Ethan Miller Note: I have covered VOXX International Corporation (NASDAQ:VOXX) previously, so investors should view this as an update to my earlier articles on the company. Leading automotive and consumer electronics products manufacturer and distributor VOXX International Corporation or “VOXX International” continues to operate in a challenging business environment as once again evidenced by the…

Read More

Michelin: Value Over Volume In Progress (OTCMKTS:MGDDF)

kenneth-cheung In our last update, we emphasized how Compagnie Générale des Établissements Michelin (OTCPK:MGDDF) (OTCPK:MGDDY) was trading at a 20% discount compared to its historical average in EV on sales, EV on EBITDA, and P/E. Aside from an attractive entry price, our buy rating was backed by the company’s ability to offset raw material price…

Read More

Credo Technology: Concentration Risk Still Overshadows Hyperscaler Progress (NASDAQ:CRDO)

Jacob Wackerhausen/iStock via Getty Images Credo Technology (NASDAQ:CRDO) is a company providing high-speed connectivity solutions, such as integrated circuits / ICs, Active Electrical Cables / AECs, and Serializer and Deserializaer / SerDes Chiplets. Share performance has been relatively strong since going public in 2022 at the price of $11 per share. Despite the demand shock…

Read More

Newmark Group: Recovery Is In Progress (NASDAQ:NMRK)

krisanapong detraphiphat/Moment via Getty Images Elevator Pitch I leave my existing Buy rating for Newmark Group (NASDAQ:NMRK) unchanged. My prior December 16, 2023, update for NMRK referred to the stock as “an undervalued capital markets recovery play.” The recovery in Newmark’s capital markets business is still in progress, which suggests there is still upside associated…

Read More

January CPI Report: Inflation Progress Stalls

Wong Yu Liang/Moment via Getty Images By Seema Shah, Chief Global Strategist The January Consumer Price Index (CPI) showed that inflation was, once again, hotter than expected, frustrating both the market and the Federal Reserve (Fed). Both headline and core monthly inflation accelerated, while the Fed’s favored supercore inflation measure extended its recent upward trend….

Read More

Progress Software Corporation (PRGS) Q4 2023 Earnings Call Transcript

Progress Software Corporation (NASDAQ:PRGS) Q4 2023 Earnings Conference Call January 16, 2024 5:00 PM ET Company Participants Michael Micciche – Vice President, Investor Relations Yogesh Gupta – Chief Executive Officer Anthony Folger – Chief Financial Officer Conference Call Participants Pinjalim Bora – JPMorgan Ittai Kidron – Oppenheimer Fatima Boolani – Citigroup Brent Thill – Jefferies…

Read More

Zurich Insurance: Farmers Turnaround In Progress And Higher Remuneration Makes It A Buy

thamerpic We participated in the Zurich Insurance Group Investor Day in London two weeks ago. Also, following the company’s Q3 results (OTCQX: ZURVY), we decided to update our long-term readers. The company released its quarterly financial release, providing a concise update on the last three months’ development. In contrast, in the Investor Day presentation, the…

Read More

Waters: Progress In Repositioning The Business, Valuation Is Much More Accommodating (WAT)

Volodymyr Kalyniuk/iStock via Getty Images For much of the last decade, life sciences tools has been a “yeah, but” sector. Meaning, yeah, the revenue growth rates have been good, business relationships tend to be sticky, margins (and return metrics like ROIC) are typically very good, and opportunities like bioprocessing / bioproduction provide an attractive runway…

Read More

Progress Software Corporation (PRGS) Q3 2023 Earnings Call Transcript

Progress Software Corporation (NASDAQ:PRGS) Q3 2023 Earnings Conference Call September 26, 2023 5:00 PM ET Company Participants Michael Micciche – Vice President, Investor Relations Yogesh Gupta – Chief Executive Officer Anthony Folger – Chief Financial Officer Conference Call Participants Ray McDonough – Guggenheim Securities Antonio Venturim – Jefferies Ittai Kidron – Oppenheimer Operator Good day…

Read More

Twist Bioscience Stock: Progress Hidden By Execution Issues And Soft Demand (NASDAQ:TWST)

ebrublue10 Twist Bioscience (NASDAQ:TWST) is slowly making progress in its core SynBio and NGS businesses, but its Biopharma business has execution issues and investment in data storage is being scaled back, potentially delaying commercialization. A greater focus on costs is leading to an improvement in margins, which should continue into FY2024 as production at the…

Read More

Viking Therapeutics: Measured Progress In Key Trials Amid Rising R&D Costs (NASDAQ:VKTX)

Wirestock/iStock via Getty Images Introduction Viking Therapeutics (NASDAQ:VKTX) is a clinical-stage biotech firm working on treatments for metabolic and endocrine issues. Their main drug, VK2809, is a thyroid hormone receptor beta agonist for non-alcoholic steatohepatitis (NASH), showing good tolerability in Phase 2b trials. Viking is also testing VK0214 for X-ALD, a rare neurological condition, and…

Read More

Wolfspeed: Focus On Progress, Not Accounting Shifts (NYSE:WOLF)

gerenme/iStock via Getty Images Wolfspeed (NYSE:WOLF) is forming a tradition of collapsing following quarterly earnings. The semiconductor company is busy building silicon carbide and related device facilities to meet surging EV and renewable energy demand, but the technology isn’t simple to implement. My investment thesis remains Bullish on the stock due to huge design-in wins,…

Read More